Kidney international
-
Kidney international · Sep 2002
Randomized Controlled Trial Clinical TrialDual renin-angiotensin system blockade at optimal doses for proteinuria.
The antiproteinuric effect of combining the angiotensin-converting enzyme (ACE) inhibitor lisinopril and the angiotensin II (Ang II) antagonist losartan was compared to that of the optimal antiproteinuric doses of monotherapy. ⋯ Dose-titration with a renin-angiotensin system blocker, followed by add-on therapy is highly effective in order to reduce proteinuria. The safety of this regimen needs to be addressed in future studies.